Hengdian Group Capital

Active

Updated: Apr 1, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Jan 26, 2026	Jixing Pharmaceuticals	$287.0M Series D	—	Adage Capital Management, HBM Healthcare Investments, Invus, RA Capital Management, Roderick Wong, Silver Arc Private Capital, SR One, SymBiosis, TCGX

Total Raised

N/A

Valuation

N/A